Rhabdoid tumor

This study tests a drug called alisertib in children and young adults (up to age 22) with rare, aggressive tumors called atypical teratoid rhabdoid tumors (AT/RT) in the brain or malignant rhabdoid tumors (MRT) elsewhere in the body. For patients whose cancer has come back or not…

This phase 2 trial tests the drug selpercatinib in children and young adults (ages 1 to 21) with advanced cancers that have a specific genetic change called a RET alteration. The goal is to see if the drug can shrink tumors or stop them from growing. Only one participant has been…

This study tests a drug called tipifarnib in children and young adults (ages 1 to 21) whose cancers have a specific change in the HRAS gene. The cancers are advanced or have come back after treatment. The goal is to see if tipifarnib can shrink tumors or stop them from growing. A…

This study tests two immunotherapy drugs, tiragolumab and atezolizumab, in children and adults with rare cancers that have come back or not responded to treatment. These cancers lack certain genes (SMARCB1 or SMARCA4), making them hard to treat. The goal is to see if the drug com…

This study tested the drug ensartinib in 13 children and young adults (ages 1–21) whose cancers had come back or did not respond to treatment and had specific ALK or ROS1 gene changes. The goal was to see if the drug could shrink or stop tumor growth. While the drug targets cance…

This early-stage trial tests a new treatment for children and young adults up to age 21 with certain brain tumors that have come back or not responded to standard therapy. The treatment uses the patient's own immune cells, which are modified in a lab to recognize and attack a pro…

This expanded access program provides tazemetostat, a drug that blocks a protein called EZH2, to adults with serious or life-threatening solid tumors that have lost the INI1 or SMARCA4 protein. Eligible patients must have tried other treatments without success and cannot join a f…

This phase 2 trial is testing two immunotherapy drugs, nivolumab and ipilimumab, in children and young adults with rare INI1-negative cancers that have come back or not responded to treatment. The study aims to see if the combination can shrink tumors or slow disease progression.…

This phase 2 trial tested the drug ivosidenib in children and young adults (ages 1 to 21) with solid tumors, lymphomas, or histiocytic disorders that have an IDH1 mutation and have either come back after treatment or not responded. The goal was to see if the drug could shrink or …

This study tests a drug called erdafitinib in children and young adults (ages 1 to 21) whose cancers have come back or are not responding to treatment and have specific changes in FGFR genes. The drug works by blocking enzymes that help cancer cells grow. The main goal is to see …

This study tests a drug called ulixertinib in children and teens whose advanced cancers have a specific genetic change in the MAPK pathway. The goal is to see if the drug can shrink or control the tumor. About 20 participants with various solid tumors, lymphomas, or related disor…

This phase 2 trial is testing the drug larotrectinib in children and young adults (ages 1 to 21) with advanced solid tumors, non-Hodgkin lymphoma, or histiocytic disorders that have a specific genetic change called an NTRK fusion. The cancers have either come back after treatment…

This clinical trial tests a risk-adapted approach for young children with newly diagnosed brain tumors. The treatment starts with chemotherapy to delay radiation, giving the brain more time to develop. Then, radiation is carefully targeted to the tumor area to reduce side effects…

This early-phase study tests a personalized cell therapy for children and young adults (up to age 26) with solid tumors that have come back or not responded to standard treatment. The therapy uses the patient's own immune cells, modified to recognize and attack a protein called B…

This study is testing a new way to choose chemotherapy for children with high-risk or relapsed soft tissue sarcomas. Doctors grow a miniature version of the patient's tumor in the lab (called an organoid) and test different drugs on it to see which works best. The goal is to see …

This study tests a combination of three drugs—tazemetostat, nivolumab, and ipilimumab—in children with rare tumors that lack the INI1 or SMARCA4 proteins. The goal is to find a safe dose and see if the drugs can shrink tumors. About 49 children with specific tumor types are being…

This early-stage trial tests a radioactive drug called CLR 131 in 30 children and young adults with solid tumors, lymphoma, or brain tumors that have come back or not responded to standard treatments. The main goals are to find a safe dose and see if the drug can shrink tumors. P…

This early-phase trial tests a new experimental treatment called CATCH T cells in up to 12 adults with certain solid tumors (like liver cancer or Wilms tumor) that have returned or not responded to standard care. The cells are the patient's own T cells, genetically modified in th…

This study tests a daily combination of sirolimus, celecoxib, and low-dose chemotherapy in 46 children whose solid or brain tumors have returned or not responded to standard treatment. The goal is to see if this approach can shrink tumors or stop them from growing. While not a cu…

This early-phase trial tests a new immunotherapy called AGAR T cells in children with solid tumors such as liver cancer, Wilms tumor, and rhabdomyosarcoma that have returned or not responded to standard care. The cells are made from the patient's own T cells, which are geneticall…

This early-phase study tests whether specially engineered immune cells (CAR T cells) can be safely given directly into the brain or spinal fluid of children and young adults with HER2-positive brain tumors that have come back or not responded to standard treatments. The therapy a…

This early-stage trial tests a new type of immunotherapy for children and young adults with solid tumors that have not responded to standard treatments. The therapy uses the patient's own immune cells (T cells) that are genetically modified to recognize and attack cancer cells ca…

This study screens children and teens with advanced solid tumors, lymphomas, or histiocytic disorders to find genetic changes in their cancer cells. Participants undergo biopsies and scans to identify mutations that can be targeted by specific drugs. The goal is to see if matchin…